Article and Video CATEGORIES

Cancer Journey

Search By

Alexandra was born in El Salvador and has always had a very strong desire to do something that allows her to help others. She has worked in Digital Marketing since 2015, gaining experience working with different clients throughout Central America and the US.

She has been involved with cancer very closely in her family and knows that there’s never enough we can do to help cancer patients and families go through this difficult path.

Leading Developments in Lung Cancer - 2023
AlexandraGBeneke
Drs. West, Lovly, and Addeo review key information from 2023 ASCO on lung cancer developments, including the results of several trials.
Author
Alexandra Guandique-Beneke
Image
2023 Leading Developments and current questions in lung cancer

For this year's post-ASCO Lung Cancer panel discussion, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center, and Founder and President of GRACE, Christine Lovly, Associate Professor of Medicine, Division of Hematology-Oncology, and Dr. Alfredo Addeo, Medical Oncologist, Department of Oncology at the University Hospital of Geneva (HUG), discuss the most current and emerging treatment information recently presented at ASCO.

To watch the complete playlist, click here.

 

 

 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Online Community

A Brief Tornado.  I love the analogy Dr. Antonoff gave us to describe her presentation.  I felt it earlier too and am looking forward to going back for deeper dive.

Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".

While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".  

I hope any...

My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.

Here's the webinar on YouTube.  It begins with the agenda. Note the link is a playlist, which will be populated with shorts from the webinar on specific topics

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

Recent Comments

JOIN THE CONVERSATION
Webinar OnDemand
By JanineT GRACE … on
My understanding of ADCs is…
By JanineT GRACE … on
Right patient, right time,…
By JanineT GRACE … on
A Brief Tornado.  I love the…
By JanineT GRACE … on